INDOCO2024-01-012024-03-31 INDOCO2024-01-012024-03-31 INDOCO2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member INDOCO2024-01-012024-03-31in-bse-fin:OneOperatingExpenses02Member INDOCO2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member INDOCO2024-01-012024-03-31in-bse-fin:FourOperatingExpenses02Member INDOCO2024-03-31 INDOCO2024-01-012024-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDOCO2024-01-012024-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDOCO2024-01-012024-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member INDOCO2024-01-012024-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532612 INDOCO NOTLISTED Indoco Remedies Limited Equity 2023-04-01 2024-03-31 2024-05-16 2024-05-08 INR Lakhs Yearly 13:15:00 14:35:00 2024-05-16 2024-05-16 true Cash Flow Indirect Declaration of unmodified opinion Single segment PHARMACEUTICALS 2024-01-01 2024-03-31 Audited Consolidated 4496400000.00 26600000.00 4523000000.00 1218000000.00 271700000.00 -80900000.00 883000000.00 120500000.00 262300000.00 1715900000.00 4390500000.00 132500000.00 197300000.00 329800000.00 106600000.00 2900000.00 109500000.00 0.00 220300000.00 0.00 0.00 0.00 0.00 220300000.00 8200000.00 228500000.00 227000000.00 -6700000.00 235200000.00 -6700000.00 184400000.00 2 2.39 2.39 0.00 0.00 2.39 2.39 0.00 0.00 0.00 1. The audited Consolidated Results for the Quarter and Year ended 31st March, 2024 have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 16th May, 2024. The Statutory Auditors have expressed an Unmodified Audit opinion on these audited Consolidated Financial Results. 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3. The Board of Directors have proposed, subject to the approval of shareholders in the ensuing Annual General Meeting a Dividend of 75% i.e. Rs. 1.50 per equity share on face value of Rs. 2/-each to its equity shareholder's for the year 2023-2024. 4. During the quarter and year ended 31st March 2024, the Nomination and Remuneration Committee of the Board at its meeting held on 29th March, 2024 has approved the grant of 90,000 Employee Stock Options and 13,000 Restricted Stock Units to the eligible employees under Indoco Remedies Limited Employee Stock Option Plan- 2022. 5. In Nomination and Remuneration Committee Meeting held on 29th March 2024, the Company has allotted 31,850 number of equity shares to Indoco Employees Welfare Trust under Indoco Remedies Limited Employee Stock Option Plan- 2022. 6. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 8. The Consolidated Financial Results includes the Results of the following Companies ----------------------------------------------------------------------------------------------------------------------------- Name of the Company % of Shareholdings Consolidated as ------------------------------------------------------------------------------------------------------------------------------ Xtend Industrial Designers & Engineers Pvt Ltd 100 Subsidiary Indoco Remedies Czech S R O 100 Subsidiary Indoco Remedies UK Ltd 100 Subsidiary Warren Remedies Private Ltd 100 Subsidiary FPP Holding Company, LLC 85 Subsidiary --------------------------------------------------------------------------------------------------------------------------------- 9. Figures for the quarter ended 31.3.2024 and 31.3.2023 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2023 (limited reviewed) and 31.12.2022 (limited reviewed). 10. (*) Exceptional items include consideration received Rs. 19.7 cr for grants to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company. Single segment 2023-04-01 2024-03-31 Audited Consolidated 18172900000.00 98500000.00 18271400000.00 4850100000.00 1156600000.00 -414800000.00 3619300000.00 380200000.00 918700000.00 6518600000.00 17028700000.00 1242700000.00 115300000.00 1358000000.00 331700000.00 56200000.00 387900000.00 0.00 970100000.00 0.00 0.00 0.00 0.00 970100000.00 2700000.00 972800000.00 984700000.00 -14600000.00 987400000.00 -14600000.00 184400000.00 2 10914600000.00 10.53 10.51 0.00 0.00 10.53 10.51 0.00 0.00 0.00 OTHER EXPENSES 1482500000.00 RESEARCH & DEVELOPMENT EXPENSE 233400000.00 OTHER EXPENSES 5547000000.00 RESEARCH & DEVELOPMENT EXPENSE 971600000.00 6000000.00 7882200000.00 1028700000.00 215200000.00 1445500000.00 219400000.00 0.00 0.00 14600000.00 31200000.00 67200000.00 113000000.00 0.00 996600000.00 11900600000.00 3530600000.00 72400000.00 4062000000.00 148600000.00 94700000.00 14900000.00 69600000.00 4462200000.00 17600000.00 1536300000.00 9546700000.00 21447300000.00 184400000.00 10914600000.00 11099000000.00 11105000000.00 3641400000.00 48900000.00 3690300000.00 336800000.00 118300000.00 73600000.00 4219000000.00 3078200000.00 1536400000.00 880300000.00 5494900000.00 144800000.00 483600000.00 6123300000.00 10342300000.00 21447300000.00 377100000.00 -270800000.00 -637800000.00 0.00 -404100000.00 -36800000.00 -55200000.00 -47600000.00 0.00 301100000.00 0.00 -51400000.00 0.00 918700000.00 0.00 -11800000.00 3400000.00 288100000.00 51300000.00 4100000.00 0.00 39600000.00 28800000.00 0.00 0.00 0.00 82600000.00 3800000.00 0.00 503900000.00 1861900000.00 0.00 0.00 0.00 294900000.00 0.00 1567000000.00 0.00 0.00 0.00 62400000.00 0.00 0.00 0.00 0.00 16800000.00 4273000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 44600000.00 0.00 -64300000.00 0.00 -4338300000.00 0.00 0.00 0.00 7700000.00 0.00 0.00 0.00 0.00 2511300000.00 -892200000.00 38300000.00 0.00 207100000.00 361400000.00 0.00 0.00 2804400000.00 33100000.00 0.00 33100000.00 115500000.00 148600000.00 ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT AND LOSS 9500000.00 ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT AND LOSS 500000.00 9500000.00 500000.00 2400000.00 100000.00 Items that may be reclassified to profit or loss 1100000.00 Items that may be reclassified to profit or loss 2300000.00 1100000.00 2300000.00 0.00 0.00